{
    "organizations": [],
    "uuid": "9e8ed07084d02111dfb6a2e2f320b95c212744db",
    "author": "",
    "url": "https://www.reuters.com/article/brief-compugen-ltd-bayer-plans-to-advanc/brief-compugen-ltd-bayer-plans-to-advance-cancer-immunotherapy-program-into-first-in-human-trials-in-2018-idUSFWN1RU0SG",
    "ord_in_thread": 0,
    "title": "BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17, 2018 / 11:08 AM / Updated 21 minutes ago BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018 Reuters Staff 1 Min Read \nApril 17 (Reuters) - Compugen Ltd: \n* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-17T14:07:00.000+03:00",
    "crawled": "2018-04-17T14:19:53.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "ltd",
        "bayer",
        "plan",
        "advance",
        "cancer",
        "immunotherapy",
        "program",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "compugen",
        "ltd",
        "compugen",
        "ltd",
        "bayer",
        "plan",
        "advance",
        "cancer",
        "immunotherapy",
        "program",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}